up to 200 pg mutated DNA. Bone marrow aspirates with various involvements of MM (range: 10-80% of marrow cellularity) were selected, and all cases have been verified by morphologic examination, immunophenotypic analysis either by flow cytometry or immunohistochemistry. All cases demonstrated to have positive immunoglobulin heavy or k light gene rearrangements. Negative and positive controls containing homozygous and heterozygous mutations of V617F were included. A total 59 bone marrow specimens from MM patients were tested for JAK2 (Val617Phe) mutation. All the tested specimens displayed a wildtype JAK-2 gene genotype, and none of the MM cells with the specific point mutation was identified ( Figure 1 ). Selected cases were verified by direct DNA sequencing. The results indicated that JAK2 (Val617Phe) mutation is very infrequently, if any, in MM cells, despite the fact that constitutional activation of JAK2 kinase as well as STAT3 phosphorylation is frequently seen in MM patients. The study suggests that JAK2 mutation V617F does not play a significant role in the pathogenesis of MM and that other yet unknown mechanisms may also involve constitutive JAK2 activation, particularly in IL-6-independent MM cells.
Note: During the preparation of this manuscript for submission, we noticed a report of similar study from Dr Fiorini et al.
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Our results are consistent with their results and confirm the conclusion that JAK2 V617F mutation is very infrequent in human MM despite the fact that constitutional activation of JAK2 kinase as well as STAT3 phosphorylation is frequently seen in MM patients. So other mechanisms, different from JAK2 V617F mutation, could explain the pathogenesis of MM. Cytokines of interleukin-6 family are major survival and growth factors in vivo and in vitro for multiple myeloma cells (MM). It induces intracellular signaling through STAT family proteins that are activated by JAK family protein tyrosine kinases. [1] [2] [3] When methods became available, we investigated the presence of JAK2 V617F mutation in MM to see if this alteration could contribute to the pathogenesis of this hematological disorder. We analysed 93 patients affected by MM mostly taken at diagnosis for the presence of JAK2 V617F mutation and we did not find any positive case. 4 Huang et al. tested DNA from bone marrow samples of 59 patients diagnosed with MM for JAK2 V617F mutation, and they did not find any positive case. All tested samples displayed a wildtype JAK2, and they concluded that JAK2 V617F mutation is very infrequent in MM despite the fact that constitutional activation of JAK2 kinase as well as STAT3 phosphorylation is frequently seen in MM patients. So other mechanisms different from JAK2 V617F mutation could explain the pathogenesis of MM.
In this study from Huang et al. the screening of JAK2 V617F mutation has been performed on bone marrow samples with a different involvement of plasma cells (range 10-80% of marrow cellularity), so that we can be sure that the analysis of the presence of mutation has been performed on malignant cells. In our study, 4 we performed screening of mutation on peripheral blood samples because we did not have bone marrow samples at diagnosis, but we explained the clonotypic relationship between bone marrow plasma cells and B-lineage blood cells in patient with MM; these B cells are CD19 þ , CD11b þ and CD34 þ , and express mRNA encoding IgH, CD19 and CD34, so that they have properties consistent with malignant status; 5 we can therefore say that our analysis is reliable too, even if it was not performed on bone marrow.
In the study from Huang et al., there are no references to criteria for diagnosis of MM and no data about patient's characteristics; we also do not know if these samples were taken at diagnosis or after treatment and during follow-up.
Huang et al. used an allele-specific PCR [6] [7] [8] followed by separation and detection with capillary electrophoresis and this test has a sensitivity up to 200 pg mutated DNA; they only sequenced selected cases. The method used has the same sensitivity as our method (allele-specific pcr), but the result is displayed by capillary electrophoresis instead of agarose gel electrophoresis.
This study confirms our previous report 4 bringing out the absence of a significant involvement of JAK2 V617F mutation in the pathogenesis of MM. The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders A recent letter in Leukemia 1 reported the detection of the JAK2 V617F mutation at very low levels in peripheral blood of healthy donors. This finding is consistent with our own data generated using TaqMan (fluorescence-based real-time PCR) and minor groove binding probes designed for the quantitative determination of DNA copy number of JAK2 V617F. 2 Apart from not using a plasmid standard curve containing the mutant allele to determine absolute copy number of JAK2 V617F, the characteristics of the previously reported assay appear very similar to our own. 2 We found that our assay, which does not employ locked nucleotide technology, exhibited good reproducibility, efficiency and the correlation coefficient of the standard curve averaged 0.97. The assay showed 100% concordance with sequence-based typing (SBT) for detecting the presence of the mutation in samples with greater than 1000 copies (n ¼ 14), and detected low levels of the mutation in three samples that showed no mutation by SBT. We also detected the presence of the mutation to less then 0.05% clinical dilution (30 copies), with a linear range extending from 10 and 300 000 copies per reaction (Figure 1) . By combining this assay with another TaqMan assay for determining cell copy number, 3 we have been able to determine the average number of JAK2 V617F mutant copies per cell and per 20 ng of DNA in absolute terms from granulocyte fractions (Figure 2 ). Quantitative determination of JAK2 V617F by either means was extremely low among healthy controls (n ¼ 18), and we assumed this to represent non-specific amplification of the wild-type allele, as shown in Figure 1 . Among patients presenting with suspected myeloproliferative disorders (n ¼ 131) some values were extremely high and included six measures greater than an average of 2.5 copies per cell from individuals. Although the y= -3.4244log10x + 31.334. 
Figure 1
Clinical dilutions of DNA from a mutation positive individual with DNA from a healthy control. The assay demonstrated sensitivity to 0.05% mutation. Amplification in healthy control samples (n ¼ 18) did not occur before 36 cycles or 30 copies. Determining the specificity of the assay is hampered by fact that we do not know whether healthy controls also carry the mutation. However, we can say that amplification of the mutation in the healthy controls occurred only after the number of cycles required to detect a 0.05% dilution of the positive sample.
